PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19228734-0	2009	Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.	Paclitaxel	92-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-41	
19228734-2	2009	Here, we studied whether overexpression of ErbB2 may lead to mitotic deregulation in breast cancer cells via up-regulation of survivin that confers Taxol resistance.	Paclitaxel	148-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-48	
19228734-3	2009	EXPERIMENTAL DESIGN: ErbB2-overexpressing and ErbB2-low-expressing breast cancer cell lines were used to compare their mitotic exit rate, survivin expression level, and apoptosis level in response to Taxol.	Paclitaxel	200-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-26	
19228734-7	2009	ErbB2-overexpressing cells exited M phase faster than ErbB2-low-expressing cells, which correlated with the increased resistance to Taxol-induced apoptosis.	Paclitaxel	132-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5	
19228734-10	2009	In addition, combination treatment of Taxol with PI3K/Akt and Src inhibitor led to increased apoptosis in ErbB2-overexpressing breast cancer cells than single treatment.	Paclitaxel	38-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-111	
19228734-11	2009	CONCLUSIONS: Survivin up-regulation by ErbB2 is a critical event in ErbB2-mediated faster mitotic exit and contributes to Taxol resistance.	Paclitaxel	122-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-44	
19228734-11	2009	CONCLUSIONS: Survivin up-regulation by ErbB2 is a critical event in ErbB2-mediated faster mitotic exit and contributes to Taxol resistance.	Paclitaxel	122-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-73